Compare Sunrun Inc (RUN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs Sana Biotechnology Inc — how do they compare? Sunrun Inc trades at $10.22 (market cap $2.42B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Sunrun Inc is far larger — about 2.1× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| RUN | SANA | |
|---|---|---|
Market Cap | $2.42B | $1.13B |
Sector | Technology | Health |
52-Week High | $21.41 | $5.92 |
52-Week Low | $9.38 | $2.68 |
Enterprise Value | $16.93B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $10.19, up 3.24% today, but faces bearish technical signals despite strong earnings beats in recent quarters. The company shows solid valuation metrics with P/E of 6.82 and P/S of 0.78, though cash flow remains negative from operations. Recent news highlights mixed sentiment with Q2 earnings beating expectations but guidance cuts weighing on investor confidence.
The outlook remains cautious with analyst consensus bullish (62% buy ratings) and a $14.38 price target suggesting 41% upside potential. Key risks include negative operating cash flow, high debt levels, and competitive pressures in the solar industry. The stock offers value opportunity but requires careful monitoring of cash generation improvements.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
